Breaking News Instant updates and real-time market news.

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Baidu (BIDU) up 8.5%. ALSO HIGHER: Nabriva (NBRV) up 22.6% after confirming FDA approval of Xenleta in CABP... Moderna (MRNA) up 9.3% after being granted FDA fast track designation for Zika vaccine... Vivint Solar (VSLR) up 1.0% after being initiated with Overweight at Keybanc. DOWN AFTER EARNINGS: Fabrinet (FN) down 14.5%... iQIYI (IQ) down 8.6%... Merus (MRUS) down 5.0%. ALSO LOWER: Sarepta (SRPT) down 12.3% after FDA rejection of DMD golodirsen. Movers as of 18:30ET.

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

BIDU Baidu
$104.28

7.63 (7.89%)

08/09/19
THCP
08/09/19
NO CHANGE
Target $135
THCP
Buy
Baidu price target lowered to $135 from $220 at TH Data Capital
TH Data Capital analyst Tian Hou lowered his price target for Baidu to $135 from $220 ahead of the company's Q2 results on August 19. Based on data and calculations, the analyst believes Baidu is likely to deliver Q2 net revenue in line with consensus but with better margin. Looking beyond quarterly earnings, however, Hou thinks 2019 is a "changing as well as a challenging year" for the company. The macro economy is weaker and competition is stronger, Hou tells investors in a research note. The analyst does not expect short-term revenue surprises but keeps a Buy rating on Baidu shares.
07/23/19
07/23/19
DOWNGRADE

Mixed
Baidu downgraded to Mixed following checks at OTR Global
As previously reported, OTR Global downgraded Baidu to Mixed from Positive. The firm's checks indicate Q2 advertising spending weakened due to softer China macroeconomic conditions, competition from short-video platforms, and lagging ROI. OTR now sees Q2 spending on Baidu search to be flat year-over-year versus up 6%-9% in Q1, and for Q3 spending to also be flat.
08/09/19
KEYB
08/09/19
NO CHANGE
Target $148
KEYB
Overweight
Baidu price target lowered to $148 from $160 at KeyBanc
KeyBanc analyst Hans Chung lowered his price target for Baidu to $148 from $160. In a research note to investors, Chung says that his firm's checks may suggest continuously low visibility of advertising demand along with the recently increased level of the U.S.-China trade war, which could negatively impact market sentiment. The analyst remains Overweight on Baidu given attractive valuation and leadership in AI technology.
08/05/19
JEFF
08/05/19
INITIATION
Target $132
JEFF
Buy
Baidu initiated with a Buy at Jefferies
Jefferies analyst Thomas Chong started Baidu with a Buy rating and $132 price target. The analyst considers 2019 a year of investment for Baidu to enhance user experience and strengthen its ecosystem. With the stock down 30% year-to-date, the analyst believes the "worst is priced in for Baidu on macro headwinds."
NBRV Nabriva Therapeutics
$2.21

-0.06 (-2.64%)

05/02/19
GABE
05/02/19
UPGRADE
GABE
Hold
Nabriva Therapeutics upgraded to Hold from Sell at Gabelli
05/01/19
NEED
05/01/19
NO CHANGE
Target $10
NEED
Buy
Nabriva Therapeutics price target lowered to $10 from $15 at Needham
Needham analyst Alan Carr lowered his price target on shares of Nabriva Therapeutics to $10 from $15 after the company announced that it received a Complete Response Letter from the FDA for the New Drug Application seeking approval of Contepo for the treatment of complicated urinary tract infections. He maintains a Buy rating on Nabriva shares.
08/16/19
HCWC
08/16/19
NO CHANGE
HCWC
H.C. Wainwright sees Q2 2020 approval for Nabriva's Contepo
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $7 price target on Nabriva Therapeutics after the company's announced its plan to resubmit its New Drug Application, or NDA, of Contepo. The analyst sees an approval decision in Q2 of 2020, assuming the NDA is resubmitted in early Q4 of19 as planned. Arce added that it was important that "the FDA did not request new clinical or non-clinical data, nor specify any concerns regarding Contepo's safety or efficacy in the Type A meeting minutes."
05/13/19
HCWC
05/13/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Nabriva ahead of expected Lefamulin approval
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $7 price target on Nabriva Therapeutics as he expects Lefamulin's FDA approval for the treatment of community-acquired bacterial pneumonia around its August 19 PDUFA date. Additionally, the analyst expects Lefamulin's EU approval in mid-2020.
MRNA Moderna
$13.41

0.235 (1.78%)

06/20/19
PIPR
06/20/19
NO CHANGE
Target $30
PIPR
Overweight
Moderna recent weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using the recent weakness in shares of Moderna as a buying opportunity. The stock is down 19% on increased volume since the initial public offering lock-up expiry on June 5, Tenthoff tells investors in a research note. The analyst is most focused on the Phase I chikungunya antibody data in the second half of 2019, which he believes will have read-through to Moderna's growing orphan disease pipeline. He reiterates an Overweight rating on the shares with a $30 price target.
08/16/19
PIPR
08/16/19
NO CHANGE
Target $30
PIPR
Overweight
Moderna should be bought ahead of catalysts, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends buying shares of Moderna on weakness ahead of the company's R&D day on September 12. Moderna has completed enrollment of the Phase I study of cytomegalovirus vaccine mRNA-1647 with data soon, and the company could also report preliminary Phase I data on intratumoral mRNA-2754 by the end of 2019, Tenthoff tells investors in a research note. Further, the analyst is focused on the Phase I chikungunya antibody mRNA-1944 data in Q4 for read-through to Moderna's orphan disease pipeline. He sees multiple clinical data readouts through the end of the year and reiterates an Overweight rating on the shares with a $30 price target.
05/29/19
OPCO
05/29/19
NO CHANGE
Target $31
OPCO
Outperform
Moderna price target raised to $31 from $27 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Moderna to $31 from $27 after spending time with management. The analyst was "consistently impressed" with the updates on safety, manufacturing, and increasing dosing experience of various Moderna therapeutics in different modalities. He reiterates an Outperform rating on the shares.
07/24/19
MSCO
07/24/19
NO CHANGE
MSCO
Warming could create need for up to $125B more vaccinations, says Morgan Stanley
Morgan Stanley analysts led by Matthew Harrison offered a report sizing the impact on biopharma from climate change. They conclude that warmer temperatures are likely to create more hospitable environments for disease transmission and they cite recent research that suggests 385M-725M more people than today may be exposed to infectious diseases such as dengue, Zika, chickungunya, and yellow fever by 2050. They estimate $50B-$125B of incremental vaccinations may be needed, but see the potential for that figure to be as high as $200B with branded pricing of more complicated vaccines. The companies best positioned to benefit from a rising need for infectious disease vaccines include Sanofi (SNY), GlaxoSmithKline (GSK), Moderna (MRNA), Merck (MRK), Johnson & Johnson's (JNJ) Janssen, Pfizer (PFE) and Takeda (TAK), according to Harrison and the team.
VSLR Vivint Solar
$8.30

0.3 (3.75%)

08/19/19
KEYB
08/19/19
INITIATION
Target $12
KEYB
Overweight
Vivint Solar initiated with an Overweight at KeyBanc
KeyBanc analyst Sophie Karp initiated Vivint Solar with an Overweight rating and $12 price target.
08/09/19
BOFA
08/09/19
NO CHANGE
Target $14
BOFA
Buy
Vivint Solar price target raised to $14 from $12.50 at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith raised his price target on Vivint Solar to $14 and kept his Buy rating after its Q2 results, saying the 56MW in deployments was above the guidance range and highlights "over a year" of "consistent" growth execution. The analyst also cites the management's confidence in the back half of the year as it raised the FY19 growth outlook to 15% and noted the "supportive tailwinds" to expand further in FY20 through a ramp in new partnerships with retailers and CA homebuiders as well as the Investment Tax Credit "safe-harbor".
05/07/19
05/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Computer Programs (CPSI) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jamie Stockton saying while the company reported "relatively weak" Q1 bookings and indicated Q2 sales and profits would be under pressure, management has worked hard to enhance the platform. 2. GW Pharmaceuticals (GWPH) upgraded to Outperform from Perform at Oppenheimer with analyst Esther Rajavelu noting the company reported "strong" Epidiolex uptake and more importantly, shared positive topline results from a Phase 3 study of Epidiolex in patients with seizures associated with tuberous sclerosis complex. 3. Vivint Solar (VSLR) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying customer demand for solar distributed generation continues to be high and larger players like Vivint will be well positioned to capture this growth. 4. CyrusOne (CONE) upgraded to Buy from Hold at Berenberg with analyst Nate Crossett stating he believes now is the time to own the stock for its outsized exposure to the European colocation market, contending that CyrusOne has the highest growth potential of the providers with a large wholesale component. 5. Duluth Holdings (DLTH) upgraded to Outperform from Neutral at Baird with analyst Jonathan Komp sayingthat while he has been disappointed by its recent financial performance, he believes reset earnings expectations and negative sentiment provide downside protection. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/19
SBSH
05/07/19
UPGRADE
Target $8.5
SBSH
Buy
Citi upgrades Vivint Solar to Buy, doubles price target to $8.50
Citi analyst Praful Mehta upgraded Vivint Solar to Buy from Neutral and doubled his price target for the shares to $8.50 from $4.25. Customer demand for solar distributed generation continues to be high and larger players like Vivint will be well positioned to capture this growth, Mehta tells investors in a research note. The analyst cites the company's growth opportunities, improved execution and lower investor return thresholds for his upgrade to Buy.
FN Fabrinet
$56.40

0.77 (1.38%)

08/09/19
NEED
08/09/19
NO CHANGE
Target $70
NEED
Buy
Fabrinet price target raised to $70 from $62 at Needham
Needham analyst Alex Henderson raised his price target on Fabrinet to $70 and kept his Buy rating ahead of its earnings on August 19th. The analyst expects a "strong print and guide", since "virtually every company" in the Optical space reported stronger than expected results this quarter. Henderson adds that the concerns related to Fabrinet's exposure to Huawei also appear to be "overdone".
07/02/19
PIPR
07/02/19
NO CHANGE
PIPR
Piper sees 'interesting opportunities' in Optical Networking space
The trade war concerns have created some "interesting opportunities" within the Optical Networking space as underlying demand trends remain solid, Piper Jaffray analyst Troy Jensen tells investors in a research note. The analyst believes investors should revisit some select names and he highlights Acacia Communications (ACIA), Fabrinet (FN) and Lumentum (LITE). He continues to view Acacia as one of the best optical stocks to own and would be buyers at current levels.
07/29/19
JPMS
07/29/19
INITIATION
Target $57
JPMS
Neutral
Fabrinet initiated with a Neutral at JPMorgan
JPMorgan analyst Samik Chatterjee started Fabrinet with a Neutral rating and $57 price target. The analyst says limited upside on margins and risks to near-term estimates from the "dynamic situation" relative to sanctions on Huawei keep him on the sidelines.
05/28/19
NEED
05/28/19
NO CHANGE
Target $62
NEED
Buy
Fabrinet price target lowered to $62 from $70 at Needham
Needham analyst Alex Henderson lowered his price target on Fabrinet (FN) to $62 to reflect the company's loss of sales to Huawei on the expected impact to Lumentum (LITE) - one of Fabrinet's largest customers. The analyst notes that although Huawei is not a direct Fabrinet customer, between Lumentum and NeoPhotonics (NPTN), about 10% of its revenue is tied to Huawei through its customers. Henderson still keeps his Buy rating on the stock with an optimistic view that a trade deal between U.S. and China will be reached "at some point."
IQ iQIYI
$18.10

1.02 (5.97%)

08/16/19
JPMS
08/16/19
INITIATION
Target $14
JPMS
Underweight
iQIYI initiated with an Underweight at JPMorgan
JPMorgan started iQIYI with an Underweight rating and $14 price target.
08/05/19
JEFF
08/05/19
INITIATION
Target $21.8
JEFF
Buy
iQIYI assumed with a Buy at Jefferies
Jefferies analyst Thomas Chong assumed coverage of iQIYI with a Buy rating and $21.80 price target. The analyst remains positive about iQIYI long term on its "strength" in original content, despite macro uncertainties and more stringent regulations. He expects the company's membership revenue to remain resilient.
08/16/19
JPMS
08/16/19
INITIATION
Target $14
JPMS
Underweight
JPMorgan startrs iQIYI with Underweight rating, $14 price target
JPMorgan analyst Alex Yao initiated coverage of iQIYI with an Underweight rating and $14 price target. "Soft" online ad demand and content supply constraints resulting in subdued new subscriber sign-ups will drive estimate cuts and share underperformance, Yao tells investors in a research note. He expects iQIYI shares to react negatively in the second half of 2019 as the company revises down 2019 subscriber guidance.
08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRUS Merus
$18.46

1.75 (10.47%)

04/03/19
04/03/19
UPGRADE
Target $23

Outperform
Merus upgraded to Outperform from Sector Perform at RBC Capital
As previously reported, RBC Capital analyst Brian Abrahams upgraded Merus to Outperform and raised his price target to $23 from $18. The analyst cites the company's continued "quiet progress" toward the second half of 2019 when it will showcase its portfolio and provide several potential value-creating events. Among the catalysts, Abrahams lists Merus' "detailed initial data from MCLA-117 in AML, updates from '128 combos in breast cancer, and progress in the clinic with '145 and '158."
04/05/19
WEDB
04/05/19
NO CHANGE
Target $25
WEDB
Outperform
Merus price target lowered to $25 from $34 at Wedbush
Wedbush analyst David Nierengarten maintained an Outperform rating on Merus but lowered his price target to $25 from $34, saying he is revising his expectations for the company's MCLA-128 in metastatic breast cancer. Overall, the analyst see Merus's early-stage Biclonics candidates as rationally designed, differentiated assets with significant upside, and looks forward to initial Phase 1 dose-escalation data from MCLA-117 in relapsed/refractory Acute Myeloid Leukemia in 2H19, as well as initial Phase 1 dose-escalation data from MCLA-158 by year end.
04/12/19
GUGG
04/12/19
INITIATION
Target $25
GUGG
Buy
Merus assumed with a Buy at Guggenheim
Guggenheim analyst Michael Schmidt assumed coverage of Merus with a Buy rating and $25 price target. The company has a "differentiated" bispecific antibody platform with rapid target screening and lead optimization technology, Schmidt tells investors in a research note. The analyst sees multiple clinical catalysts for the company through the second half of 2019 and "considerable potential upside to valuation if any single program is successful."
06/28/19
ROTH
06/28/19
INITIATION
Target $20
ROTH
Buy
Merus initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler initiated Merus with a Buy rating and $20 price target, noting that his valuation is based only on MCLA-128, the only one of the company's programs that has presented clinical data to date. Merus has several antibodies that harness the immune system to treat and potentially cure various types of cancer in the clinic, including MCLA-117 and MCLA-158, and those could provide upside to his current valuation, noted the analyst.
SRPT Sarepta
$120.16

-4.81 (-3.85%)

08/16/19
CHDN
08/16/19
UPGRADE
Target $10
CHDN
Buy
Chardan upgrades Solid Biosciences to Buy after IGNITE DMD trial update
As previously reported, Chardan analyst Gbolahan Amusa upgraded Solid Biosciences (SLDB) to Buy from Neutral after the company provided an update on the IGNITE DMD phase I/II study of its AAV-based gene therapy, SGT-001, for Duchenne muscular dystrophy. The company's update and trial protocol changes suggest to the analyst that concerns on SGT-001 may be addressable, which may mean Solid is still positioned to address potential manufacturing constraints in the AAV-based gene therapy DMD space. Amusa noted that Sarepta Therapeutics (SRPT) utilizes less-scalable adherent processes that may limit supply and may mean Sarepta's product could cost more per patient to manufacture. Amusa raised the price target on Solid shares to $10 from $7.50.
08/09/19
FBCO
08/09/19
NO CHANGE
Target $207
FBCO
Outperform
Credit Suisse says 'no change' to Sarepta thesis on SRP-9001 FAERS event
Credit Suisse analyst Martin Auster said there is "no change" to his thesis on Sarepta Therapeutics after speaking with the company's management after the company said that an adverse event report was erroneously submitted to the FDA's adverse event reporting system, or FAERs. In a research note to investors, Auster, who has an Outperform rating and $207 price target on Sarepta shares, says management said the patient in question was reported to have been highly active the previous day and subsequently presented to his clinician with dark urine, elevated CK, no muscle pain and was otherwise asymptomatic. Management said that the urine and CK measures resolved to baseline and the patient was discharged from the hospital on the next day. Auster says overall, he thinks the reported AE concern was a non-event and that the lack of any DSMB or FDA action as a result strengthens the credibility of the company's position.
08/19/19
LEER
08/19/19
UPGRADE
Target $15
LEER
Outperform
Solid Biosciences upgraded to Outperform with $15 target at SVB Leerink
As previously reported, SVB Leerink analyst Joseph Schwartz upgraded Solid Biosciences (SLDB) to Outperform from Market Perform after reassessing the protocol amendments and enrollment progress communicated by the company for its Phase 1/2 IGNITE-DMD trial. He believes much of the concerns that have weighed on the stock are baked-in at this point and continues to believe that Solid's scalable manufacturing "could be an underappreciated X-factor" that could potentially help it catch-up to the leader in the DMD space, Sarepta (SRPT). Schwartz raised his price target on Solid shares to $15 from $8.
08/08/19
PIPR
08/08/19
NO CHANGE
PIPR
Sarepta selloff on FAERS report 'smells fishy,' says Piper Jaffray
Shares of Sarepta Therapeutics dropped over 12% before being halted following news of a FDA Adverse Event Reporting System report that a patient was hospitalized with rhabdomyolysis after being administered their Duchenne muscular dystrophy gene therapy, Piper Jaffray analyst Danielle Brill tells investors in a research note. This "whole thing smells fishy," considering the event occurred in February 2019, the FAERS database is not intended for investigational drugs, and DMD patients are at an increased risk for rhabdomyolysis, says the analyst. She believes it is more likely that the event was related to the disease than Sarepta's gene therapy treatment. Brill has an Overweight rating on Sarepta, which halted for news this afternoon down $17.94 to $124.32.

TODAY'S FREE FLY STORIES

IDA

IDACORP

$111.26

0.93 (0.84%)

16:36
09/20/19
09/20
16:36
09/20/19
16:36
Hot Stocks
IDACORP raises quarterly dividend to 67c from 63c per share »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

MO

Altria Group

$40.80

0.69 (1.72%)

16:33
09/20/19
09/20
16:33
09/20/19
16:33
Hot Stocks
Altria Group recommends rejection of amended mini-tender by TRC »

Altria Group states it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, AL

Air Lease

$42.68

-0.615 (-1.42%)

16:32
09/20/19
09/20
16:32
09/20/19
16:32
Hot Stocks
Air Lease announces delivery of new A321-200neo to Air Astana »

Air Lease Corporation…

EADSY

Airbus

$0.00

(0.00%)

AL

Air Lease

$42.68

-0.615 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

16:30
09/20/19
09/20
16:30
09/20/19
16:30
Options
Preliminary option volume of 23.5M today »

Preliminary option volume…

PSX

Phillips 66

$103.26

0.14 (0.14%)

16:28
09/20/19
09/20
16:28
09/20/19
16:28
Periodicals
Phillips 66 says Beaumont oil terminal ops still shut down, Reuters says »

Phillips 66 said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

POST

Post Holdings

$105.73

0.335 (0.32%)

16:24
09/20/19
09/20
16:24
09/20/19
16:24
Hot Stocks
Post files IPO for active nutrition unit BellRing Brands »

Post Holdings, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/20/19
09/20
16:20
09/20/19
16:20
Options
Closing CBOE SPX and VIX Index summary for September 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELS

Equity Lifestyle

$134.26

1.22 (0.92%)

16:19
09/20/19
09/20
16:19
09/20/19
16:19
Hot Stocks
Equity Lifestyle announces two-for-one stock split »

Equity Lifestyle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/20/19
09/20
16:17
09/20/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$13.52

-0.11 (-0.81%)

16:16
09/20/19
09/20
16:16
09/20/19
16:16
Hot Stocks
Fiat Chrysler COO Paul Alcala to retire effective September 30 »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/20/19
09/20
16:16
09/20/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$0.13

-0.0017 (-1.29%)

16:15
09/20/19
09/20
16:15
09/20/19
16:15
Syndicate
Breaking Syndicate news story on Sellas Life Sciences »

Sellas Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$527.88

-4.44 (-0.83%)

16:11
09/20/19
09/20
16:11
09/20/19
16:11
Hot Stocks
TransDigm provides update on divestitures »

TransDigm Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

16:10
09/20/19
09/20
16:10
09/20/19
16:10
General news
Treasury Market Summary »

Treasury Market Summary:…

AAPL

Apple

$218.51

-2.4 (-1.09%)

, MCD

McDonald's

$210.05

-0.51 (-0.24%)

16:08
09/20/19
09/20
16:08
09/20/19
16:08
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. markets closed out…

AAPL

Apple

$218.51

-2.4 (-1.09%)

MCD

McDonald's

$210.05

-0.51 (-0.24%)

FB

Facebook

$189.46

-0.69 (-0.36%)

FIT

Fitbit

$4.13

0.46 (12.55%)

GOOG

Alphabet

$1,230.65

-8.95 (-0.72%)

GOOGL

Alphabet Class A

$1,230.42

-7.79 (-0.63%)

WMT

Walmart

$116.92

-0.12 (-0.10%)

MO

Altria Group

$40.78

0.67 (1.67%)

BTI

British American Tobacco

$36.29

-0.21 (-0.58%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$71.50

-0.2 (-0.28%)

MDR

McDermott

$2.02

0.44 (27.85%)

CRC

California Resources

$11.08

1.18 (11.92%)

ROKU

Roku

$107.49

-26.22 (-19.61%)

W

Wayfair

$122.82

-5.845 (-4.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Oct

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

BPMX

BioPharmX

$0.39

0.008 (2.12%)

16:08
09/20/19
09/20
16:08
09/20/19
16:08
Hot Stocks
BioPharmX receives extension to regain compliance with NYSE »

BioPharmX received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKIS

Peak Resorts

$10.99

0.005 (0.05%)

, MTN

Vail Resorts

$235.28

1.31 (0.56%)

16:06
09/20/19
09/20
16:06
09/20/19
16:06
Hot Stocks
Peak Resorts holders approve merger pact for acquisition by Vail Resorts »

Peak Resorts, Inc. (SKIS)…

SKIS

Peak Resorts

$10.99

0.005 (0.05%)

MTN

Vail Resorts

$235.28

1.31 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

SPKE

Spark Energy

$10.07

0.06 (0.60%)

16:04
09/20/19
09/20
16:04
09/20/19
16:04
Syndicate
Breaking Syndicate news story on Spark Energy »

Spark Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$10.07

0.06 (0.60%)

16:02
09/20/19
09/20
16:02
09/20/19
16:02
Syndicate
Breaking Syndicate news story on Spark Energy »

Spark Energy files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTFT

Future FinTech

$1.01

-0.02 (-1.95%)

16:01
09/20/19
09/20
16:01
09/20/19
16:01
Hot Stocks
Future FinTech submits compliance plan to Nasdaq »

Future FinTech Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SALM

Salem Media

$1.65

-0.115 (-6.52%)

15:34
09/20/19
09/20
15:34
09/20/19
15:34
Syndicate
Breaking Syndicate news story on Salem Media »

Salem Media files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SALM

Salem Media

$1.65

-0.115 (-6.52%)

15:34
09/20/19
09/20
15:34
09/20/19
15:34
Syndicate
Breaking Syndicate news story on Salem Media »

Salem Media files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRC

Bank of Marin

$42.89

-0.63 (-1.45%)

15:31
09/20/19
09/20
15:31
09/20/19
15:31
Hot Stocks
Bank of Marin engages Korn Ferry for CEO successor search »

Bank of Marin and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$5.78

-0.08 (-1.37%)

15:30
09/20/19
09/20
15:30
09/20/19
15:30
Options
Long-term deep otm puts in Transocean see action »

Long-term deep otm puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$155.47

-0.26 (-0.17%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:29
09/20/19
09/20
15:29
09/20/19
15:29
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT),…

IWM

iShares Trust Russell 2000 Index Fund

$155.47

-0.26 (-0.17%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.